Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15918554 | 0.81 | MRGPRX4 (0.44) | MRGPRX4 | |
| SCHEMBL20652835 | 0.80 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL22208776 | 0.79 | SCN8A (0.40) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9367408 | 0.79 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4KMT2A | |
| SCHEMBL1656288 | 0.78 | PLAU (0.46) | PLAUL3MBTL1 | |
| SCHEMBL20639088 | 0.76 | NPC1 (0.49) | — | |
| SCHEMBL20644195 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4ARMEN1 | |
| SCHEMBL16398705 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4ARMEN1 | |
| SCHEMBL22208662 | 0.76 | SCN8A (0.41) | SLC6A2SLC6A3SLC6A4MRGPRX4 | |
| SCHEMBL16398592 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111065383-A | Carboxamides useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| EP-3022175-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | SLC6A2 240/4885SLC6A3 293/4885SLC6A4 195/4885 |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN5A | SLC6A2 240/4885SLC6A3 293/4885SLC6A4 195/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SLC6A2 270/4885SLC6A3 420/4885SLC6A4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.